C. Greg Guyer compensation by year
BIOMARIN PHARMACEUTICAL Summary Compensation Table · all 4 fiscal years held| Component | FY2020 | FY2021 | FY2023 | FY2025 |
|---|---|---|---|---|
| Salary | $392,308 | $600,000 | $662,308 | $697,115 |
| Bonus | $250,000 | $500,000 | $0 | $0 |
| Stock awards | $3,166,214 | $2,858,206 | $3,817,386 | $3,464,162 |
| Option awards | $2,109,894 | $817,979 | $769,518 | $954,810 |
| Non-equity incentive | $262,500 | $558,000 | $422,100 | $546,000 |
| Pension and deferred compensation | $0 | $0 | $0 | $0 |
| All other | $162,583 | $93,064 | $29,807 | $29,593 |
| Total | $6,343,499 | $5,427,248 | $5,701,119 | $5,691,680 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: BIOMARIN PHARMACEUTICAL INC DEF 14A filed April 21, 2026, accession 0001628280-26-026290, and prior-year filings. Open the filing on EDGAR.
How this page was built: the BIOMARIN PHARMACEUTICAL INC filed document, accession 0001628280-26-026290. Every figure is read from that document and cited to the page and table it appears in. Filed April 21, 2026.
Equity holdings
unvested awards at FY2023 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 11,840 | $1,141,613 | — |
| RSU | 11,040 | $1,064,477 | — |
| RSU | 10,420 | $1,004,696 | — |
| RSU | 8,900 | $858,138 | — |
| RSU | 8,760 | $844,639 | — |
| RSU | 8,280 | $798,358 | — |
| RSU | 6,250 | $602,625 | — |
| RSU | 5,520 | $532,238 | — |
| RSU | 5,210 | $502,348 | — |
| RSU | 4,450 | $429,069 | — |
| RSU | 4,170 | $402,071 | — |
| Option | 6,683 | — | $90.36 |
Per the Outstanding Equity Awards at Fiscal Year-End table in BIOMARIN PHARMACEUTICAL INC's FY2023 proxy; value at the fiscal year-end close, as the company printed it. The 12 largest of 15 award rows shown.
BIOMARIN PHARMACEUTICAL’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| Alexander Hardy | President and Chief Executive Officer | $21,927,563 |
| Gregory Friberg | Executive Vice President and Chief Research & Development Officer | $7,174,583 |
| Brian Mueller | Executive Vice President and Chief Financial Officer | $6,831,812 |
| Cristin Hubbard | Executive Vice President and Chief Commercial Officer | $5,713,695 |
| C. Greg Guyer · this page | Executive Vice President and Chief Technical Officer | $5,691,680 |
C. Greg Guyer's compensation dossier, BIOMARIN PHARMACEUTICAL
You have read C. Greg Guyer's totals and holdings. The dossier adds each equity grant BIOMARIN PHARMACEUTICAL disclosed for C. Greg Guyer and BIOMARIN PHARMACEUTICAL's own disclosed peer group, where the company discloses them, with every row in a PDF and a CSV cited to its filing.
See an example →The full BIOMARIN PHARMACEUTICAL compensation record
free company briefThis page is one person within BIOMARIN PHARMACEUTICAL's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the BIOMARIN PHARMACEUTICAL proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order BIOMARIN PHARMACEUTICAL's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are BIOMARIN PHARMACEUTICAL's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order BMRN
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.